First-line crizotinib therapy combined with local brain treatment can improve intracranial PFS for ALK-positive NSCLC with brain metastases.This finding should be confirmed further through multicenter, prospective clinical trials with large sample size. This evidence concerns the gene ALK and non-small cell lung carcinoma.